FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID™

HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA)
These highlights of the EUA do not include all the information needed to use PAXLOVID™ under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for PAXLOVID.

PAXLOVID (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use
Original EUA Authorized Date: 12/2021

RECENT MAJOR CHANGES
How Supplied/Storage and Handling (16, 17): addition of nirmatrelvir 150 mg/ritonavir 100 mg dose pack 04/2022
Drug Interactions (7.3, 12.3): addition of new drug interactions 04/2022
Warnings and Precautions (5.2, 17): addition of hypersensitivity including anaphylaxis 02/2022
Adverse Reactions (6.2): addition of post-authorization experience section 02/2022

EUA FOR PAXLOVID
The U.S. Food and Drug Administration has issued an EUA for the emergency use of the unapproved PAXLOVID which includes nirmatrelvir, a SARS-CoV-2 main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

LIMITATIONS OF AUTHORIZED USE
• PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19.
• PAXLOVID is not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
• PAXLOVID is not authorized for use longer than 5 consecutive days.

PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which PAXLOVID belongs (i.e., anti-infectives).

PAXLOVID is not approved for any use, including for use as treatment of COVID-19. (1)

PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

See Full Fact Sheet for Healthcare Providers for the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19.

DOSAGE AND ADMINISTRATION
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. (2.1)
Nirmatrelvir must be co-administered with ritonavir. (2.1)
• Initiate PAXLOVID treatment as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. (2.1)
• Administer orally with or without food. (2.1)
• Dosage: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all three tablets taken together twice daily for 5 days. (2.1)
• Dose reduction for moderate renal impairment (eGFR ≥30 to <60 mL/min): 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), with both tablets taken together twice daily for 5 days. (2.2)
• PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min). (2.2, 8.6)
• PAXLOVID is not recommend in patients with severe hepatic impairment (Child-Pugh Class C). (2.3, 8.7)

DOSAGE FORMS AND STRENGTHS
• Tablets: nirmatrelvir 150 mg (3)
• Tablets: ritonavir 100 mg (3)

CONTRAINDICATIONS
• History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. (4)
• Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. (4, 7.3)
• Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (4)

WARNINGS AND PRECAUTIONS
• The concomitant use of PAXLOVID and certain other drugs may result in potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions. (5.1, 7)
• Allergic Reactions/Hypersensitivity: Hypersensitivity reactions have been reported with PAXLOVID. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care. (5.2)
• Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. (5.3)
• HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. (5.4)

ADVERSE REACTIONS
Adverse events (incidence ≥1% and ≥5 subject difference) were dysgeusia, diarrhea, hypertension, and myalgia. (6.1)

You or your designee must report all SERIOUS ADVERSE EVENTS or MEDICATION ERRORS potentially related to PAXLOVID (1) by submitting FDA Form 3500 online, (2) by downloading this form and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form. Please also provide a copy of this form to Pfizer Inc. at fax number: 1-866-635-8337. (6.4)

DRUG INTERACTIONS
Co-administration of PAXLOVID can alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of PAXLOVID. Consider the potential for drug interactions prior to and during PAXLOVID therapy and review concomitant medications during PAXLOVID therapy. (2.4, 4, 5.1, 7, 12.3)

See FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS.
FULL FACT SHEET FOR HEALTHCARE PROVIDERS

1  EMERGENCY USE AUTHORIZATION

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk\(^1\) for progression to severe COVID-19, including hospitalization or death.

LIMITATIONS OF AUTHORIZED USE

- PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19 [see Dosage and Administration (2.1)].\(^2\)
- PAXLOVID is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
- PAXLOVID is not authorized for use for longer than 5 consecutive days.

PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which PAXLOVID belongs (i.e., anti-infectives).

PAXLOVID is not approved for any use, including for use for the treatment of COVID-19.

PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Justification for Emergency Use of Drugs During the COVID-19 Pandemic

There is currently an outbreak of COVID-19 caused by SARS-CoV-2, a novel coronavirus. The Secretary of Health and Human Services (HHS) has declared that:

- Circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic (March 27, 2020 declaration).

An EUA is a U.S. Food and Drug Administration authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include:

---

\(^1\) For information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the Centers for Disease Control and Prevention (CDC) website: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Healthcare providers should consider the benefit-risk for an individual patient.

\(^2\) Patients requiring hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID may complete the full 5-day treatment course per the healthcare provider’s discretion.

Revised: 14 April 2022
• The biological agent(s) can cause a serious or life-threatening disease or condition;
• Based on the totality of the available scientific evidence (including data from adequate and well-controlled clinical trials, if available), it is reasonable to believe that
  o the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and
  o the known and potential benefits of the product—when used to diagnose, prevent, or treat such disease or condition—outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s);
• There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition.

Information Regarding Available Alternatives for the EUA Authorized Use

Veklury (remdesivir) is FDA-approved for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, who are not hospitalized and have mild-to-moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Veklury is administered via intravenous infusion for a total treatment duration of 3 days.

Although Veklury is an approved alternative treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, FDA does not consider Veklury to be an adequate alternative to PAXLOVID for this authorized use because it may not be feasible or practical for certain patients (e.g., it requires an intravenous infusion daily for 3 days).

Other therapeutics are currently authorized for the same use as PAXLOVID. For additional information on all products authorized for treatment or prevention of COVID-19, please see https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

For information on clinical studies that are testing the use of PAXLOVID in COVID-19, please see www.clinicaltrials.gov.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage for Emergency Use of PAXLOVID

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets.

Nirmatrelvir must be co-administered with ritonavir. Failure to correctly co-administer nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect.

The dosage for PAXLOVID is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.
The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset. Should a patient require hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID, the patient should complete the full 5-day treatment course per the healthcare provider’s discretion.

If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.

PAXLOVID (both nirmatrelvir and ritonavir tablets) can be taken with or without food [see Clinical Pharmacology (12.3)]. The tablets should be swallowed whole and not chewed, broken, or crushed.

2.2 Important Dosing Information in Patients with Renal Impairment

No dosage adjustment is needed in patients with mild renal impairment (eGFR ≥60 to <90 mL/min). In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min), the dosage of PAXLOVID is 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days [see How Supplied/Storage and Handling (16)]. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions [see Patient Counseling Information (17)].

PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min) until more data are available; the appropriate dosage for patients with severe renal impairment has not been determined [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

2.3 Use in Patients with Hepatic Impairment

No dosage adjustment is needed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe hepatic impairment (Child-Pugh Class C); therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

2.4 Important Drug Interactions with PAXLOVID

No dosage adjustment is required when co-administered with other products containing ritonavir or cobicistat.

Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.

Refer to other sections of the Fact Sheet for important drug interactions with PAXLOVID. Consider the potential for drug interactions prior to and during PAXLOVID therapy and review concomitant medications during PAXLOVID therapy [see Contraindications (4), Warnings and Precautions (5.1), and Drug Interactions (7)].
3 DOSAGE FORMS AND STRENGTHS

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets.

- Nirmatrelvir is supplied as oval, pink immediate-release, film-coated tablets debossed with “PFE” on one side and “3CL” on the other side. Each tablet contains 150 mg of nirmatrelvir.

- Ritonavir is supplied as white or white to off-white film-coated tablets uniquely identified by the color, shape, and debossing [see How Supplied/Storage and Handling (16)]. Each tablet contains 100 mg of ritonavir.

4 CONTRAINDICATIONS

PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.

PAXLOVID is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.3)]:

- Alpha₁-adrenoreceptor antagonist: alfuzosin
- Analgesics: pethidine, propoxyphene
- Antianginal: ranolazine
- Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine
- Anti-gout: colchicine
- Antipsychotics: lurasidone, pimozide, clozapine
- Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
- HMG-CoA reductase inhibitors: lovastatin, simvastatin
- PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension (PAH)
- Sedative/hypnotics: triazolam, oral midazolam

PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer [see Drug Interactions (7.3)]:

- Anticancer drugs: apalutamide
- Anticonvulsant: carbamazepine, phenobarbital, phenytoin
- Antimycobacterials: rifampin
- Herbal products: St. John’s Wort (hypericum perforatum)

5 WARNINGS AND PRECAUTIONS

There are limited clinical data available for PAXLOVID. Serious and unexpected adverse events may occur that have not been previously reported with PAXLOVID use.
5.1 Risk of Serious Adverse Reactions Due to Drug Interactions

Initiation of PAXLOVID, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A.

Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of PAXLOVID, respectively.

These interactions may lead to:

- Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.
- Clinically significant adverse reactions from greater exposures of PAXLOVID.
- Loss of therapeutic effect of PAXLOVID and possible development of viral resistance.

See Table 1 for clinically significant drug interactions, including contraindicated drugs. Consider the potential for drug interactions prior to and during PAXLOVID therapy; review concomitant medications during PAXLOVID therapy and monitor for the adverse reactions associated with the concomitant medications [see Contraindications (4) and Drug Interactions (7)].

5.2 Allergic Reactions/Hypersensitivity

Hypersensitivity reactions have been reported with PAXLOVID including urticaria, angioedema, dyspnea, mild skin eruptions, and pruritus. Cases of anaphylaxis, TEN, and Stevens-Johnson syndrome have also been reported with ritonavir, a component of PAXLOVID (refer to NORVIR prescribing information). If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care.

5.3 Hepatotoxicity

Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis.

5.4 Risk of HIV-1 Resistance Development

Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection [see Dosage and Administration (2.4), Contraindications (4), and Drug Interactions (7)].

6 ADVERSE REACTIONS

6.1 Adverse Reactions from Clinical Studies

The following adverse reactions have been observed in the clinical studies of PAXLOVID that supported the EUA. The adverse reaction rates observed in these clinical studies cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in
clinical practice. Additional adverse events associated with PAXLOVID may become apparent with more widespread use.

The safety of PAXLOVID is based on data from Study C4671005 (EPIC-HR), a Phase 2/3 randomized, placebo-controlled trial in non-hospitalized adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection [see Clinical Studies (14.1)]. A total of 2,224 symptomatic adult subjects 18 years of age and older who are at high risk of developing severe COVID-19 illness received at least one dose of either PAXLOVID (n=1,109) or placebo (n=1,115). Adverse events were those reported while subjects were on study medication and through Day 34 after initiating study treatment. PAXLOVID [300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir] or matching placebo were to be taken twice daily for 5 days.

Adverse events (all grades regardless of causality) in the PAXLOVID group (≥1%) that occurred at a greater frequency (≥5 subject difference) than in the placebo group were dysgeusia (6% and <1%, respectively), diarrhea (3% and 2%), hypertension (1% and <1%), and myalgia (1% and <1%).

The proportions of subjects who discontinued treatment due to an adverse event were 2% in the PAXLOVID group and 4% in the placebo group.

6.2 Post-Authorization Experience

The following adverse reactions have been identified during post-authorization use of PAXLOVID. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Hypersensitivity reactions [see Warnings and Precautions (5.2)]

6.4 Required Reporting for Serious Adverse Events and Medication Errors

The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all serious adverse events* and medication errors potentially related to PAXLOVID within 7 calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA requires that such reports, using FDA Form 3500, include the following:

- Patient demographics and baseline characteristics (e.g., patient identifier, age or date of birth, gender, weight, ethnicity, and race).
- A statement "PAXLOVID use for COVID-19 under Emergency Use Authorization (EUA)" under the "Describe Event, Problem, or Product Use/Medication Error" heading.
- Information about the serious adverse event or medication error (e.g., signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to the occurrence of the event, duration of the event, treatments required to mitigate the event, evidence of event improvement/disappearance after stopping or reducing the dosage, evidence of event reappearance after reintroduction, clinical outcomes).
- Patient’s pre-existing medical conditions and use of concomitant products.
- Information about the product (e.g., dosage, route of administration, NDC #).

Submit adverse event and medication error reports, using Form 3500, to FDA MedWatch using one of the following methods:
• Complete and submit the report online: https://www.fda.gov/medwatch/report.htm
• Complete and submit a postage-paid FDA Form 3500 (https://www.fda.gov/media/76299/download) and return by:
  o Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
  o Fax to 1-800-FDA-0178, or
• Call 1-800-FDA-1088 to request a reporting form

In addition, please provide a copy of all FDA MedWatch forms to:

<table>
<thead>
<tr>
<th>Website</th>
<th>Fax number</th>
<th>Telephone number</th>
</tr>
</thead>
</table>

The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory responses to requests from FDA for information about adverse events and medication errors following receipt of PAXLOVID.

*Serious adverse events are defined as:

• Death;
• A life-threatening adverse event;
• Inpatient hospitalization or prolongation of existing hospitalization;
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
• A congenital anomaly/birth defect;
• Other important medical event, which may require a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly.

6.5 Other Reporting Requirements

Healthcare facilities and providers will report therapeutics information and utilization data as directed by the U.S. Department of Health and Human Services.

7 DRUG INTERACTIONS

7.1 Potential for PAXLOVID to Affect Other Drugs

PAXLOVID (nirmatrelvir co-packaged with ritonavir) is an inhibitor of CYP3A and may increase plasma concentrations of drugs that are primarily metabolized by CYP3A. Co-administration of PAXLOVID with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated [see Contraindications (4) and Table 1]. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 1.

7.2 Potential for Other Drugs to Affect PAXLOVID

Nirmatrelvir and ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce PAXLOVID therapeutic effect.
7.3 Established and Other Potentially Significant Drug Interactions

Table 1 provides listing of clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult appropriate references for comprehensive information [see Contraindications (4)].

Table 1: Established and Other Potentially Significant Drug Interactions

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs within Class</th>
<th>Effect on Concentration</th>
<th>Clinical Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha 1-adrenoreceptor antagonist</td>
<td>alfuzosin</td>
<td>↑ alfuzosin</td>
<td>Co-administration contraindicated due to potential hypotension [see Contraindications (4)].</td>
</tr>
<tr>
<td>Analgesics</td>
<td>pethidine, propoxyphene</td>
<td>↑ pethidine ↑ propoxyphene</td>
<td>Co-administration contraindicated due to potential for serious respiratory depression or hematologic abnormalities [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antianginal</td>
<td>ranolazine</td>
<td>↑ ranolazine</td>
<td>Co-administration contraindicated due to potential for serious and/or life-threatening reactions [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>amiodarone, dronedarone, flecainide, propafenone, quinidine</td>
<td>↑ antiarrhythmic</td>
<td>Co-administration contraindicated due to potential for cardiac arrhythmias [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>bepridil, lidocaine (systemic)</td>
<td>↑ antiarrhythmic</td>
<td>Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.</td>
</tr>
<tr>
<td>Anticancer drugs</td>
<td>apalutamide</td>
<td>↓ nirmatrelvir/ritonavir</td>
<td>Co-administration contraindicated due to potential loss of virologic response and possible resistance [see Contraindications (4)].</td>
</tr>
<tr>
<td>Anticancer drugs</td>
<td>abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine</td>
<td>↑ anticancer drug</td>
<td>Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation. Avoid use of neratinib, venetoclax or ibrutinib. Co-administration of vincristine and vinblastine may lead to significant hematologic or gastrointestinal side effects. For further information, refer to individual product label for anticancer drug.</td>
</tr>
</tbody>
</table>

Revised: 14 April 2022
Table 1: Established and Other Potentially Significant Drug Interactions

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs within Class</th>
<th>Effect on Concentration</th>
<th>Clinical Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulants</td>
<td>warfarin</td>
<td>↑↓ warfarin</td>
<td>Closely monitor INR if co-administration with warfarin is necessary.</td>
</tr>
<tr>
<td></td>
<td>rivaroxaban</td>
<td>↑ rivaroxaban</td>
<td>Increased bleeding risk with rivaroxaban. Avoid concomitant use.</td>
</tr>
<tr>
<td></td>
<td>dabigatran&lt;sup&gt;a&lt;/sup&gt;</td>
<td>↑ dabigatran</td>
<td>Increased bleeding risk with dabigatran. Depending on dabigatran indication and renal function, reduce dose of dabigatran or avoid concomitant use. Refer to the dabigatran product label for further information.</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>carbamazepine&lt;sup&gt;a&lt;/sup&gt;, phenobarbital, phenytoin</td>
<td>↓ nirmatrelvir/ritonavir ↑ carbamazepine ↓ phenobarbital ↓ phenytoin</td>
<td>Co-administration contraindicated due to potential loss of virologic response and possible resistance [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>bupropion</td>
<td>↓ bupropion and active metabolite hydroxy-bupropion</td>
<td>Monitor for an adequate clinical response to bupropion.</td>
</tr>
<tr>
<td></td>
<td>trazodone</td>
<td>↑ trazodone</td>
<td>Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. A lower dose of trazodone should be considered. Refer to trazodone product label for further information.</td>
</tr>
<tr>
<td>Antifungals</td>
<td>voriconazole, ketoconazole, isavuconazonium sulfate</td>
<td>↓ voriconazole ↑ ketoconazole ↑ isavuconazonium sulfate ↑ itraconazole ↑ nirmatrelvir/ritonavir</td>
<td>Avoid concomitant use of voriconazole. Refer to ketoconazole, isavuconazonium sulfate, and itraconazole product labels for further information.</td>
</tr>
<tr>
<td>Anti-gout</td>
<td>colchicine</td>
<td>↑ colchicine</td>
<td>Co-administration contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment [see Contraindications (4)].</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Drugs within Class</td>
<td>Effect on Concentration</td>
<td>Clinical Comments</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Anti-HIV protease inhibitors</td>
<td>amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, saquinavir, tipranavir</td>
<td>↑ protease Inhibitor</td>
<td>For further information, refer to the respective protease inhibitors’ prescribing information. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events with concomitant use of these protease inhibitors [see Dosage and Administration (2.4)].</td>
</tr>
<tr>
<td>Anti-HIV</td>
<td>didanosine, delavirdine, efavirenz, maraviroc, nevirapine, raltegravir, zidovudine bictegravir/ emtricitabine/ tenofovir</td>
<td>↑ didanosine ↑ efavirenz ↑ maraviroc ↓ raltegravir ↓ zidovudine ↑ bictegravir ↔ emtricitabine ↑ tenofovir</td>
<td>For further information, refer to the respective anti-HIV drugs prescribing information.</td>
</tr>
<tr>
<td>Anti-infective</td>
<td>clarithromycin, erythromycin</td>
<td>↑ clarithromycin ↑ erythromycin</td>
<td>Refer to the respective prescribing information for anti-infective dose adjustment.</td>
</tr>
<tr>
<td>Antimycobacterial</td>
<td>rifampin</td>
<td>↓ nirmatrelvir/ritonavir</td>
<td>Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antimycobacterial</td>
<td>bedaquiline</td>
<td>↑ bedaquiline</td>
<td>Refer to the bedaquiline product label for further information.</td>
</tr>
<tr>
<td></td>
<td>rifabutin</td>
<td>↑ rifabutin</td>
<td>Refer to rifabutin product label for further information on rifabutin dose reduction.</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>lurasidone, pimozide, clozapine</td>
<td>↑ lurasidone ↑ pimozide ↑ clozapine</td>
<td>Co-administration contraindicated due to serious and/or life-threatening reactions such as cardiac arrhythmias [see Contraindications (4)].</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>quetiapine</td>
<td>↑ quetiapine</td>
<td>If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations.</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Drugs within Class</td>
<td>Effect on Concentration</td>
<td>Clinical Comments</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>amlodipine, diltiazem, felodipine, nicardipine, nifedipine</td>
<td>↑ calcium channel blocker</td>
<td>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID. If co-administered, refer to individual product label for calcium channel blocker for further information.</td>
</tr>
<tr>
<td>Cardiac glycosides</td>
<td>digoxin</td>
<td>↑ digoxin</td>
<td>Caution should be exercised when co-administering PAXLOVID with digoxin, with appropriate monitoring of serum digoxin levels. Refer to the digoxin product label for further information.</td>
</tr>
<tr>
<td>Endothelin receptor Antagonists</td>
<td>bosentan</td>
<td>↑ bosentan</td>
<td>Discontinue use of bosentan at least 36 hours prior to initiation of PAXLOVID. Refer to the bosentan product label for further information.</td>
</tr>
<tr>
<td>Ergot derivatives</td>
<td>dihydroergotamine, ergotamine, methylergonovine</td>
<td>↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine</td>
<td>Co-administration contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system [see Contraindications (4)].</td>
</tr>
<tr>
<td>Hepatitis C direct acting antivirals</td>
<td>elbasvir/grazoprevir, glecaprevir/pibrentasvir</td>
<td>↑ antiviral</td>
<td>Increased grazoprevir concentrations can result in ALT elevations. It is not recommended to co-administer ritonavir with glecaprevir/pibrentasvir. Refer to the ombitasvir/paritaprevir/ritonavir and dasabuvir label for further information. Refer to the sofosbuvir/velpatasvir/voxilaprevir product label for further information. Patients on ritonavir-containing HCV regimens should continue their</td>
</tr>
</tbody>
</table>
Table 1: Established and Other Potentially Significant Drug Interactions

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs within Class</th>
<th>Effect on Concentration</th>
<th>Clinical Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbal products</td>
<td>St. John’s Wort <em>(hypericum perforatum)</em></td>
<td>↓ nirmatrelvir/ritonavir</td>
<td>Co-administration contraindicated due to potential loss of virologic response and possible resistance [see Contraindications (4)].</td>
</tr>
<tr>
<td>HMG-CoA reductase inhibitors</td>
<td>lovastatin, simvastatin</td>
<td>↑ lovastatin ↑ simvastatin</td>
<td>Co-administration contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications (4)]. Discontinue use of lovastatin and simvastatin at least 12 hours prior to initiation of PAXLOVID, during the 5 days of PAXLOVID treatment and for 5 days after completing PAXLOVID.</td>
</tr>
<tr>
<td>HMG-CoA reductase inhibitors</td>
<td>atorvastatin, rosuvastatin</td>
<td>↑ atorvastatin ↑ rosuvastatin</td>
<td>Consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with PAXLOVID. Atorvastatin and rosuvastatin do not need to be held prior to or after completing PAXLOVID.</td>
</tr>
<tr>
<td>Hormonal contraceptive</td>
<td>ethinyl estradiol</td>
<td>↓ ethinyl estradiol</td>
<td>An additional, non-hormonal method of contraception should be considered during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>cyclosporine, tacrolimus, sirolimus</td>
<td>↑ cyclosporine ↑ tacrolimus ↑ sirolimus</td>
<td>Therapeutic concentration monitoring is recommended for immunosuppressants. Avoid use of PAXLOVID when close monitoring of immunosuppressant serum concentrations is not feasible. Avoid concomitant use of sirolimus and PAXLOVID. If co-administered, refer to individual product label for immunosuppressant for further information.</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Drugs within Class</td>
<td>Effect on Concentration</td>
<td>Clinical Comments</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Long-acting beta-adrenoceptor agonist</td>
<td>salmeterol</td>
<td>↑ salmeterol</td>
<td>Co-administration is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr>
<td>Narcotic analgesics</td>
<td>fentanyl</td>
<td>↑ fentanyl</td>
<td>Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl is concomitantly administered with PAXLOVID. Monitor methadone-maintained patients closely for evidence of withdrawal effects and adjust the methadone dose accordingly.</td>
</tr>
<tr>
<td></td>
<td>methadone</td>
<td>↓ methadone</td>
<td></td>
</tr>
<tr>
<td>PDE5 inhibitor</td>
<td>sildenafil (Revatio®) when used for pulmonary arterial hypertension</td>
<td>↑ sildenafil</td>
<td>Co-administration contraindicated due to the potential for sildenafil associated adverse events, including visual abnormalities hypotension, prolonged erection, and syncope [see Contraindications (4)].</td>
</tr>
<tr>
<td>Sedative/hypnotics</td>
<td>triazolam, oral midazolam a</td>
<td>↑ triazolam ↑ midazolam</td>
<td>Co-administration contraindicated due to potential for extreme sedation and respiratory depression [see Contraindications (4)].</td>
</tr>
<tr>
<td>Sedative/hypnotics</td>
<td>midazolam (administered parenterally)</td>
<td>↑ midazolam</td>
<td>Co-administration of midazolam (parenteral) should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Refer to the midazolam product label for further information.</td>
</tr>
<tr>
<td>Systemic corticosteroids</td>
<td>betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, prednisone, triamcinolone</td>
<td>↑ corticosteroid</td>
<td>Increased risk for Cushing’s syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.</td>
</tr>
</tbody>
</table>

a. See Pharmacokinetics, Drug Interaction Studies Conducted with Nirmatrelvir and Ritonavir (12.3).
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available human data on the use of nirmatrelvir during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage (see Data). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations).

In an embryo-fetal development study with nirmatrelvir, reduced fetal body weights following oral administration of nirmatrelvir to pregnant rabbits were observed at systemic exposures (AUC) approximately 10 times higher than clinical exposure at the authorized human dose of PAXLOVID. No other adverse developmental outcomes were observed in animal reproduction studies with nirmatrelvir at systemic exposures (AUC) greater than or equal to 3 times higher than clinical exposure at the authorized human dose of PAXLOVID (see Data).

In animal reproduction studies with ritonavir, no evidence of adverse developmental outcomes was observed following oral administration of ritonavir to pregnant rats and rabbits at doses (based on body surface area conversions) or systemic exposures (AUC) greater than or equal to 3 times higher than clinical doses or exposure at the authorized human dose of PAXLOVID (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo-fetal Risk
COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.

Data

Human Data

Ritonavir
Based on prospective reports to the antiretroviral pregnancy registry of live births following exposure to ritonavir-containing regimens (including over 3,400 live births exposed in the first-trimester and over 3,500 live births exposed in the second and third trimesters), there was no difference in the rate of overall birth defects for ritonavir compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The prevalence of birth defects in live births was 2.3% (95% confidence interval [CI]: 1.9%-2.9%) following first-trimester exposure to ritonavir-containing regimens and 2.9% (95% CI: 2.4%-3.6%) following second and third trimester exposure to ritonavir-containing regimens. While placental transfer of
ritonavir and fetal ritonavir concentrations are generally low, detectable levels have been observed in cord blood samples and neonate hair.

Animal Data

Nirmatrelvir
Embryo-fetal developmental (EFD) toxicity studies were conducted in pregnant rats and rabbits administered oral nirmatrelvir doses of up to 1,000 mg/kg/day during organogenesis [on Gestation Days (GD) 6 through 17 in rats and 6 through 19 in rabbits]. No biologically significant developmental effects were observed in the rat EFD study. At the highest dose of 1,000 mg/kg/day, the systemic nirmatrelvir exposure (AUC$_{24}$) in rats was approximately 8 times higher than clinical exposures at the authorized human dose of PAXLOVID. In the rabbit EFD study, lower fetal body weights (9% decrease) were observed at 1,000 mg/kg/day in the absence of significant maternal toxicity findings. At 1,000 mg/kg/day, the systemic exposure (AUC$_{24}$) in rabbits was approximately 10 times higher than clinical exposures at the authorized human dose of PAXLOVID. No other significant developmental toxicities (malformations and embryo-fetal lethality) were observed at up to the highest dose tested, 1,000 mg/kg/day. No developmental effects were observed in rabbits at 300 mg/kg/day resulting in systemic exposure (AUC$_{24}$) approximately 3 times higher than clinical exposures at the authorized human dose of PAXLOVID. A pre- and postnatal developmental (PPND) study in pregnant rats administered oral nirmatrelvir doses of up to 1,000 mg/kg/day from GD 6 through Lactation Day (LD) 20 is ongoing and only interim data through postnatal day (PND) 56 are currently available. Although no difference in body weight was noted at birth when comparing offspring born to nirmatrelvir treated versus control animals, a decrease (8% in males and females) in the body weight of offspring was observed at PND 17. No significant differences in offspring body weight were observed from PND 28 to PND 56. The maternal systemic exposure (AUC$_{24}$) at 1,000 mg/kg/day was approximately 8 times higher than clinical exposures at the authorized human dose of PAXLOVID. No body weight changes in the offspring were noted at 300 mg/kg/day, resulting in systemic exposure (AUC$_{24}$) approximately 5 times higher than clinical exposures at the authorized human dose of PAXLOVID.

Ritonavir
Ritonavir was administered orally to pregnant rats (at 0, 15, 35, and 75 mg/kg/day) and rabbits (at 0, 25, 50, and 110 mg/kg/day) during organogenesis (on GD 6 through 17 and 6 through 19, respectively). No evidence of teratogenicity due to ritonavir was observed in rats and rabbits at systemic exposures (AUC) approximately 4 times higher than exposure at the authorized human dose of PAXLOVID. Increased incidences of early resorptions, ossification delays, and developmental variations, as well as decreased fetal body weights were observed in rats in the presence of maternal toxicity, at systemic exposures approximately 4 times higher than exposure at the authorized human dose of PAXLOVID. A slight increase in the incidence of cryptorchidism was also noted in rats (at a maternally toxic dose) at an exposure approximately 5 times the exposure at the authorized human dose of PAXLOVID. In rabbits, resorptions, decreased litter size, and decreased fetal weights were observed at maternally toxic doses approximately 11 times higher than the authorized human dose of PAXLOVID, based on a body surface area conversion factor. In a pre- and postnatal development study in rats, administration of 0, 15, 35, and 60 mg/kg/day ritonavir from GD 6 through postnatal day 20 resulted in no developmental toxicity, at ritonavir doses 3 times higher than the authorized human dose of PAXLOVID, based on a body surface area conversion factor.
8.2 Lactation

Risk Summary

There are no available data on the presence of nirmatrelvir in human or animal milk, the effects on the breastfed infant, or the effects on milk production. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir (see Data). Limited published data reports that ritonavir is present in human milk. There is no information on the effects of ritonavir on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Data

In the pre- and postnatal developmental study, body weight decreases (up to 8%) were observed in the offspring of pregnant rats administered nirmatrelvir at maternal systemic exposure (AUC$_{24}$) approximately 8 times higher than clinical exposures at the authorized human dose of PAXLOVID. No body weight changes in the offspring were noted at maternal systemic exposure (AUC$_{24}$) approximately 5 times higher than clinical exposures at the authorized human dose of PAXLOVID.

8.3 Females and Males of Reproductive Potential

Contraception

Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception [see Drug Interactions (7.3)].

8.4 Pediatric Use

PAXLOVID is not authorized for use in pediatric patients younger than 12 years of age or weighing less than 40 kg. The safety and effectiveness of PAXLOVID have not been established in pediatric patients. The authorized adult dosing regimen is expected to result in comparable serum exposures of nirmatrelvir and ritonavir in patients 12 years of age and older and weighing at least 40 kg as observed in adults, and adults with similar body weight were included in the trial EPIC-HR [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14)].

8.5 Geriatric Use

Clinical studies of PAXLOVID include subjects 65 years of age and older and their data contributes to the overall assessment of safety and efficacy [see Adverse Reactions (6.1) and Clinical Studies (14.1)]. Of the total number of subjects in EPIC-HR randomized to receive PAXLOVID (N=1,120), 13% were 65 years of age and older and 3% were 75 years of age and older.

8.6 Renal Impairment

Systemic exposure of nirmatrelvir increases in renally impaired patients with increase in the severity of renal impairment [see Clinical Pharmacology (12.3)].
No dosage adjustment is needed in patients with mild renal impairment. In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min), reduce the dose of PAXLOVID to 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days. *Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID.* Providers should counsel patients about renal dosing instructions [see Patient Counseling Information (17)].

PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min based on CKD-EPI formula) until more data are available; the appropriate dosage for patients with severe renal impairment has not been determined.

### 8.7 Hepatic Impairment

No dosage adjustment of PAXLOVID is needed for patients with either mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe hepatic impairment (Child-Pugh Class C), therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

### 10 OVERDOSAGE

Treatment of overdose with PAXLOVID should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with PAXLOVID.

### 11 DESCRIPTION

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor, and ritonavir is an HIV-1 protease inhibitor and CYP3A inhibitor.

**Nirmatrelvir**

The chemical name of active ingredient of nirmatrelvir is (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide. It has a molecular formula of C_{23}H_{32}F_{3}N_{5}O_{4} and a molecular weight of 499.54. Nirmatrelvir has the following structural formula:

![Nirmatrelvir Structural Formula](image)

Nirmatrelvir is available as immediate-release, film-coated tablets. Each tablet contains 150 mg nirmatrelvir with the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate. The following are the
ingredients in the film coating: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide.

**Ritonavir**

Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1 methylethyl)-4-thiazoyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12- tetraazatridecan-13-oic acid, 5-thiazolymethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C_{37}H_{48}N_{6}O_{5}S_{2}, and its molecular weight is 720.95. Ritonavir has the following structural formula:

![Ritonavir Structure](image)

Ritonavir is available as film-coated tablets. Each tablet contains 100 mg ritonavir with the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. The film coating may include the following ingredients: colloidal anhydrous silica, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol, polysorbate 80, talc, and titanium dioxide.

**12 CLINICAL PHARMACOLOGY**

**12.1 Mechanism of Action**

Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing polyprotein precursors, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay with a \( K_i \) value of 3.1 nM and an IC\(_{50}\) value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography.

Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.

**12.3 Pharmacokinetics**

The pharmacokinetics of nirmatrelvir/ritonavir have been studied in healthy subjects.

Ritonavir is administered with nirmatrelvir as a pharmacokinetic enhancer resulting in higher systemic concentrations and longer half-life of nirmatrelvir, thereby supporting a twice daily administration regimen.

Upon oral administration of nirmatrelvir/ritonavir, the increase in systemic exposure appears to be less than dose proportional up to 750 mg as a single dose and up to 500 mg twice daily as multiple doses. Twice daily dosing over 10 days achieved steady-state on Day 2 with approximately 2-fold accumulation. The pharmacokinetic properties of nirmatrelvir/ritonavir are displayed in Table 2.
Table 2: Pharmacokinetic Properties of Nirmatrelvir and Ritonavir in Healthy Subjects

<table>
<thead>
<tr>
<th>PK Parameter (units)</th>
<th>Nirmatrelvir (When Given With Ritonavir)</th>
<th>Ritonavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$T_{\text{max}}$ (h), median</td>
<td>3.00$^a$</td>
<td>3.98$^a$</td>
</tr>
<tr>
<td>Distribution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% bound to human plasma proteins</td>
<td>69%</td>
<td>98-99%</td>
</tr>
<tr>
<td>Blood-to-plasma ratio</td>
<td>0.60</td>
<td>0.14$^c$</td>
</tr>
<tr>
<td>$V_z/F$ (L), mean</td>
<td>104.7$^b$</td>
<td>112.4$^b$</td>
</tr>
<tr>
<td>Elimination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major route of elimination</td>
<td>Renal elimination$^d$</td>
<td>Hepatic metabolism</td>
</tr>
<tr>
<td>Half-life (t$^{1/2}$) (hr), mean</td>
<td>6.05$^a$</td>
<td>6.15$^a$</td>
</tr>
<tr>
<td>Oral clearance (CL/F), mean</td>
<td>8.99$^b$</td>
<td>13.92$^b$</td>
</tr>
<tr>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic pathways</td>
<td>Minimal$^d$</td>
<td>Major CYP3A4, Minor CYP2D6</td>
</tr>
<tr>
<td>Excretion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% drug-related material in feces</td>
<td>35.3%$^e$</td>
<td>86.4%$^f$</td>
</tr>
<tr>
<td>% drug-related material in urine</td>
<td>49.6%$^e$</td>
<td>11.3%$^f$</td>
</tr>
</tbody>
</table>

a. Represents data after a single dose of 300 mg nirmatrelvir (2 x 150 mg tablet formulation) administered together with 100 mg ritonavir tablet in healthy subjects.
b. 300 mg nirmatrelvir (oral suspension formulation) and 100 mg ritonavir (tablet formulation) administered together twice a day for 3 days.
c. Red blood cell to plasma ratio.
d. Nirmatrelvir is a CYP3A4 substrate but when dosed with ritonavir metabolic clearance is minimal.
e. Determined by $^{19}$F-NMR analysis following 300 mg oral suspension enhanced with 100 mg ritonavir at -12 hours, 0 hours, 12 hours, and 24 hours.
f. Determined by $^{14}$C analysis following 600 mg $^{14}$C-ritonavir oral solution.

Single dose pharmacokinetic data of PAXLOVID in healthy subjects is depicted below (Table 3).

Table 3: Single Dose Pharmacokinetics of Nirmatrelvir Following Dosing with 300 mg/100 mg Nirmatrelvir/Ritonavir in Healthy Subjects

<table>
<thead>
<tr>
<th>PK Parameter (units)</th>
<th>Nirmatrelvir (N=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ ($\mu$g/mL)</td>
<td>2.21 (33)</td>
</tr>
<tr>
<td>$AUC_{\text{inf}}$ ($\mu$g*hr/mL)</td>
<td>23.01 (23)</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (hr)</td>
<td>3.00 (1.02-6.00)</td>
</tr>
<tr>
<td>$T_{1/2}$ (hr)</td>
<td>6.05 ± 1.79</td>
</tr>
</tbody>
</table>

Represents data from 2 x 150 mg tablets of nirmatrelvir. Values are presented as geometric mean (geometric % CV) except median (range) for $T_{\text{max}}$ and arithmetic mean ± SD for $T_{1/2}$.

Effect of Food on Oral Absorption of Nirmatrelvir

Dosing with a high fat meal modestly increased the exposure of nirmatrelvir (approximately 15% increase in mean $C_{\text{max}}$ and 1.6% increase in mean $AUC_{\text{last}}$) relative to fasting conditions following administration of a suspension formulation of nirmatrelvir co-administered with ritonavir tablets.

Specific Populations

The pharmacokinetics of nirmatrelvir/ritonavir based on age and gender have not been evaluated.
**Pediatric Patients**
The pharmacokinetics of nirmatrelvir/ritonavir in patients less than 18 years of age have not been evaluated.

Using a population PK model, the dosing regimen is expected to result in comparable steady-state plasma exposure of nirmatrelvir in patients 12 years of age and older and weighing at least 40 kg to those observed in adults after adjusting for body weight.

**Racial or Ethnic Groups**
Systemic exposure in Japanese subjects was numerically lower but not clinically meaningfully different than those in Western subjects.

**Patients with Renal Impairment**
An open-label study compared nirmatrelvir/ritonavir pharmacokinetics in healthy adult subjects and subjects with mild (eGFR ≥60 to <90 mL/min), moderate (eGFR ≥30 to <60 mL/min), and severe (eGFR <30 mL/min) renal impairment following administration of a single oral dose of nirmatrelvir 100 mg enhanced with ritonavir 100 mg administered at -12, 0, 12, and 24 hours. Compared to healthy controls with no renal impairment, the $C_{\text{max}}$ and $\text{AUC}_{\text{inf}}$ of nirmatrelvir in patients with mild renal impairment was 30% and 24% higher, in patients with moderate renal impairment was 38% and 87% higher, and in patients with severe renal impairment was 48% and 204% higher, respectively (Table 4).

<table>
<thead>
<tr>
<th>Renal Function</th>
<th>Normal Renal Function (n=8)</th>
<th>Mild Renal Impairment (n=8)</th>
<th>Moderate Renal Impairment (n=8)</th>
<th>Severe Renal Impairment (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (µg/mL)</td>
<td>1.60 (31)</td>
<td>2.08 (29)</td>
<td>2.21 (17)</td>
<td>2.37 (38)</td>
</tr>
<tr>
<td>$\text{AUC}_{\text{inf}}$ (µg*hr/mL)</td>
<td>14.46 (20)</td>
<td>17.91 (30)</td>
<td>27.11 (27)</td>
<td>44.04 (33)</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (hr)</td>
<td>2.0 (1.0 - 4.0)</td>
<td>2.0 (1.0 – 3.0)</td>
<td>2.50 (1.0 – 6.0)</td>
<td>3.0 (1.0 - 6.1)</td>
</tr>
<tr>
<td>$T_{1/2}$ (hr)</td>
<td>7.73 ± 1.82</td>
<td>6.60 ± 1.53</td>
<td>9.95 ± 3.42</td>
<td>13.37 ± 3.32</td>
</tr>
</tbody>
</table>

Values are presented as geometric mean (geometric % CV) except median (range) for $T_{\text{max}}$ and arithmetic mean ± SD for $T_{1/2}$.

**Patients with Hepatic Impairment**
A single oral dose of 100 mg nirmatrelvir enhanced with 100 mg ritonavir at -12 hours, 0 hours, 12 hours and 24 hours in subjects with moderate hepatic impairment resulted in similar exposures compared to subjects with normal hepatic function (Table 5).

<table>
<thead>
<tr>
<th>Hepatic Function</th>
<th>Normal Hepatic Function (n=8)</th>
<th>Moderate Hepatic Impairment (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (µg/mL)</td>
<td>1.89 (20)</td>
<td>1.92 (48)</td>
</tr>
<tr>
<td>$\text{AUC}_{\text{inf}}$ (µg*hr/mL)</td>
<td>15.24 (36)</td>
<td>15.06 (43)</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (hr)</td>
<td>2.0 (0.6 - 2.1)</td>
<td>1.5 (1.0 - 2.0)</td>
</tr>
<tr>
<td>$T_{1/2}$ (hr)</td>
<td>7.21 ± 2.10</td>
<td>5.45 ± 1.57</td>
</tr>
</tbody>
</table>

Values are presented as geometric mean (geometric % CV) except median (range) for $T_{\text{max}}$ and arithmetic mean ± SD for $T_{1/2}$.

Nirmatrelvir/ritonavir has not been studied in patients with severe hepatic impairment.
Drug Interaction Studies Conducted with Nirmatrelvir

*In vitro data* indicates that nirmatrelvir is a substrate for human MDR1 (P-gp) and 3A4, but not a substrate for human BCRP, MATE1, MATE2K, NTCP, OAT1, OAT2, OAT3, OCT1, OCT2, PEPT1, OATPs 1B1, 1B3, 2B1, or 4C1.

Nirmatrelvir does not reversibly inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 *in vitro* at clinically relevant concentrations. Nirmatrelvir has the potential to reversibly and time-dependently inhibit CYP3A4 and inhibit MDR1 (P-gp).

Nirmatrelvir does not induce any CYPs at clinically relevant concentrations.

Drug Interaction Studies Conducted with Ritonavir

*In vitro* studies indicate that ritonavir is mainly a substrate of CYP3A. Ritonavir also appears to be a substrate of CYP2D6 which contributes to the formation of isopropylthiazole oxidation metabolite M-2.

Ritonavir is an inhibitor of CYP3A and to a lesser extent CYP2D6. Ritonavir appears to induce CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2B6 as well as other enzymes, including glucuronosyl transferase.

The effects of co-administration of PAXLOVID with itraconazole (CYP3A inhibitor) and carbamazepine (CYP3A inducer) on the nirmatrelvir AUC and C$_\text{max}$ are summarized in Table 6 (effect of other drugs on nirmatrelvir).

### Table 6: Drug Interactions: Pharmacokinetic Parameters for Nirmatrelvir in the Presence of the Co-administered Drugs

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Co-administered Drug</th>
<th>Nirmatrelvir/ Ritonavir</th>
<th>N</th>
<th>Percent Ratio (in combination with co-administered drug/alone) of Nirmatrelvir Pharmacokinetic Parameters (90% CI); No Effect=100</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose (Schedule)</td>
<td></td>
<td></td>
<td>C$_\text{max}$</td>
</tr>
<tr>
<td>Carbamazepine$^b$</td>
<td>300 mg twice daily (16 doses)</td>
<td>300 mg/100 mg twice daily (5 doses)</td>
<td>9</td>
<td>56.82 (47.04, 68.62)</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>200 mg once daily (8 doses)</td>
<td>300 mg/100 mg twice daily (5 doses)</td>
<td>11</td>
<td>118.57 (112.50, 124.97)</td>
</tr>
</tbody>
</table>

Abbreviations: AUC=area under the plasma concentration-time curve; CI=confidence interval; C$_\text{max}$=maximum plasma concentrations.

a. For carbamazepine, AUC=AUC$_\text{inf}$, for itraconazole, AUC=AUC$_\text{tau}$.

b. Carbamazepine titrated up to 300 mg twice daily on Day 8 through Day 15 (e.g., 100 mg twice daily on Day 1 through Day 3 and 200 mg twice daily on Day 4 through Day 7).

The effects of co-administration of PAXLOVID with midazolam (CYP3A4 substrate) or dabigatran (P-gp substrate) on the midazolam and dabigatran AUC and C$_\text{max}$, respectively, are summarized in Table 7.
Table 7: Effect of Nirmatrelvir/Ritonavir on Pharmacokinetics of Co-administered Drug

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Dose (Schedule)</th>
<th>Nirmatrelvir/ Ritonavir</th>
<th>Percent Ratio of Test/Reference of Geometric Means (90% CI); No Effect=100</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Co-administered</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2 mg (1 dose)</td>
<td>300 mg/100 mg twice daily (9 doses)</td>
<td>10</td>
</tr>
<tr>
<td>Dabigatran&lt;sup&gt;b&lt;/sup&gt;</td>
<td>75 mg (1 dose)</td>
<td>300 mg/100 mg twice daily (5 doses)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>24</td>
</tr>
</tbody>
</table>

Abbreviations: AUC=area under the plasma concentration-time curve; CI=confidence interval; \(C_{\text{max}}\)=maximum plasma concentrations.

a. AUC=AUC<sub>inf</sub> for both midazolam and dabigatran.

b. For midazolam, Test=nirmatrelvir/ritonavir plus midazolam, Reference=Midazolam. Midazolam is an index substrate for CYP3A4. For dabigatran, Test=nirmatrelvir/ritonavir plus dabigatran, Reference=Dabigatran. Dabigatran is an index substrate for P-gp.

12.4 Microbiology

Antiviral Activity

Nirmatrelvir exhibited antiviral activity against SARS-CoV-2 (USA-WA1/2020 isolate) infection of differentiated normal human bronchial epithelial (dNHBE) cells with EC<sub>50</sub> and EC<sub>90</sub> values of 62 nM and 181 nM, respectively, after 3 days of drug exposure.

Nirmatrelvir had similar cell culture antiviral activity (EC<sub>50</sub> values ≤3-fold relative to USA-WA1/2020) against SARS-CoV-2 isolates belonging to the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Mu (B.1.621), and Omicron (B.1.1.529/BA.1) variants. The Beta (B.1.351) variant was the least susceptible tested variant with approximately 3-fold reduced susceptibility relative to the USA-WA1/2020 isolate.

Antiviral Activity Against SARS-CoV-2 in Animal Models

Nirmatrelvir showed antiviral activity in BALB/c and 129 mice infected with mouse-adapted SARS-CoV-2. Oral administration of nirmatrelvir at 300 mg/kg or 1,000 mg/kg twice daily initiated 4 hours post-inoculation or 1,000 mg/kg twice daily initiated 12 hours post-inoculation resulted in reduction of lung viral titer and ameliorated indicators of disease (weight loss and lung pathology) compared to placebo-treated animals.

Antiviral Resistance

Phenotypic assessments were conducted to characterize the impact of naturally occurring SARS-CoV-2 Mpro polymorphisms on the activity of nirmatrelvir in a biochemical assay using recombinant Mpro enzyme. The clinical significance of these polymorphisms is unknown, and it is also unknown if results from the biochemical assay are predictive of antiviral activity in cell culture. The following Mpro amino acid substitutions were associated with reduced nirmatrelvir activity (≥3-fold higher Ki values): G15S (4.4-fold), T135I (3.5-fold), S144A (91.9-fold), H164N (6.4-fold), H172Y (233-fold), Q189K (65.4-fold), and D248E (3.7-fold). G15S is present in the Lambda variant, which did not have reduced susceptibility to nirmatrelvir (relative to USA-WA1/2020) in cell culture.
In addition, three SARS-CoV-2 Mpro amino acid positions where polymorphisms have not been naturally observed were evaluated by substituting alanine at these positions and assessing their impact on activity in biochemical assays. These Mpro amino acid substitutions were associated with reduced nirmatrelvir activity (i.e., higher \( K_i \) values): Y54A (23.6-fold), F140A (39.0-fold), and E166A (33.4-fold). The clinical significance of substitutions at these Mpro positions is unknown.

Cell culture resistance selection studies with nirmatrelvir using mouse hepatitis virus (MHV, a betacoronavirus used as a surrogate) resulted in the emergence of Mpro amino acid substitutions: P15A, T50K, P55L, F126L, T129M, and/or S144A. The presence of the substitutions P55L and S144A in MHV Mpro was associated with reduced nirmatrelvir susceptibility (~4- to 5-fold higher \( EC_{50} \) values). These positions correspond to E55 and S144 in SARS-CoV-2 Mpro, respectively. E55L alone did not affect nirmatrelvir activity against SARS-CoV-2 Mpro in a biochemical assay, while S144A reduced nirmatrelvir activity by 91.9-fold (based on \( K_i \) value). The clinical relevance of these changes is not known.

Among subjects in clinical trial EPIC-HR with sequence analysis data available at both baseline and a post-dose sample (n=361 nirmatrelvir/ritonavir-treated, n=402 placebo-treated), the following SARS-CoV-2 Mpro or Mpro cleavage site amino acid changes were detected as treatment-emergent substitutions that were more common in nirmatrelvir/ritonavir-treated subjects relative to placebo-treated subjects (n=number of nirmatrelvir/ritonavir-treated subjects with emergent substitution): Mpro substitutions: A7S/T/V (n=3), L30F (n=3), M82I/R (n=3), G109E/R/V (n=3), P132L/S (n=4), C145F/R/Y (n=3), D153H/Y (n=3), E166V (n=3), T196A/K/M/R (n=4), W207L/S/del (n=5), A260D/T/V (n=8), D263E (n=3), A266P/V (n=3), and V297A/F/del (n=3); Mpro ORF1ab cleavage site substitutions: Q5324H/R (n=3), A5328P/S (n=6), and T6449I/P (n=3). None of these substitutions in Mpro gene or cleavage regions occurred in PAXLOVID-treated participants who also experienced hospitalization. Thus, the clinical significance of these substitutions is unknown. In a biochemical assay, the P132H/L/S, A260V, and A266V Mpro substitutions did not reduce nirmatrelvir activity (\( K_i \) fold-change ≤1, <1, and ~2, respectively). The potential phenotypic effect on nirmatrelvir susceptibility for the other substitutions is unknown.

Cross-Resistance

Cross-resistance is not expected between nirmatrelvir and anti-SARS-CoV-2 monoclonal antibodies or remdesivir based on their different mechanisms of action.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Nirmatrelvir

Carcinogenicity studies have not been conducted with nirmatrelvir.

Nirmatrelvir was negative for mutagenic or clastogenic activity in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using S. typhimurium and E. coli, the in vitro micronucleus assay using human lymphoblastoid TK6 cells, and the in vivo rat micronucleus assays.

In a fertility and early embryonic development study, nirmatrelvir was administered orally to male and female rats at doses of 60, 200, or 1,000 mg/kg/day once daily beginning 14 days prior to mating, throughout the mating phase, and continued through GD 6 for females and for a total of 32 doses for...
males. There were no effects on fertility, reproductive performance, or early embryonic development at doses up to 1,000 mg/kg/day, resulting in systemic exposure (AUC$_{24}$) approximately 4 times higher than exposure at the authorized human dose of PAXLOVID.

**Ritonavir**

Carcinogenicity studies in mice and rats have been conducted on ritonavir. In male mice, at levels of 50, 100, or 200 mg/kg/day, there was a dose dependent increase in the incidence of both adenomas and combined adenomas and carcinomas in the liver. Based on AUC measurements, the exposure at the high dose was approximately 2 times higher (in males) than the exposure in humans at the authorized human dose of PAXLOVID. There were no carcinogenic effects seen in females at the dosages tested. The exposure at the high dose was approximately 4 times higher (in females) than the exposure in humans at the authorized human dose of PAXLOVID. In rats dosed at levels of 7, 15, or 30 mg/kg/day, there were no carcinogenic effects. In this study, the exposure at the high dose was approximately 36% that of the exposure in humans at the authorized human dose of PAXLOVID.

Ritonavir was found to be negative for mutagenic or clastogenic activity in a battery of *in vitro* and *in vivo* assays including the Ames bacterial reverse mutation assay using *S. typhimurium* and *E. coli*, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.

Ritonavir produced no effects on fertility in rats at drug exposures approximately 2 (male) and 4 (female) times higher than the exposure in humans at the authorized human dose of PAXLOVID.

**13.2 Animal Toxicology and/or Pharmacology**

Studies with nirmatrelvir included repeat dose toxicity studies in rats (14 days) and monkeys (15 days). Repeated daily oral dosing in rats at up to 1,000 mg/kg/day resulted in non-adverse hematological, liver, and thyroid effects. All of the hematology and coagulation findings (i.e., increases in PT and APTT) had no clinical or microscopic correlates and all findings completely recovered at the end of the 2-week recovery period. The liver (i.e., minimal to mild periportal hepatocyte hypertrophy and vacuolation) and thyroid gland (i.e., thyroid follicular cell hypertrophy) findings were consistent with secondary adaptive effects related to microsomal enzyme-induced increase in thyroid hormone clearance in the liver, a mechanism that rats are known to be particularly sensitive to relative to humans. All of the findings observed in the liver and thyroid were low severity and occurred in the absence of correlating alterations in clinical pathology parameters, and all of these findings fully recovered. No adverse effects were observed at doses up to 1,000 mg/kg/day, resulting in systemic exposure approximately 4 times higher than exposures at the authorized human dose of PAXLOVID. Nirmatrelvir-related findings following repeat oral dosing in monkeys for 15 days were limited to emesis and increase in fibrinogen. Increased fibrinogen may be attributed to an inflammatory state but lacked a microscopic correlate. At the high dose of 600 mg/kg/day, the systemic exposure in monkeys was about 18 times higher than exposures at the authorized human dose of PAXLOVID.

**14 CLINICAL STUDIES**

**14.1 Efficacy in Subjects at High Risk of Progressing to Severe COVID-19 Illness**

The data supporting this EUA are based on the analysis of EPIC-HR (NCT04960202), a Phase 2/3, randomized, double-blind, placebo-controlled study in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of
age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI >25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Subjects with COVID-19 symptom onset of ≤5 days were included in the study. Subjects were randomized (1:1) to receive PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo orally every 12 hours for 5 days. The study excluded individuals with a history of prior COVID-19 infection or vaccination. The primary efficacy endpoint was the proportion of subjects with COVID-19 related hospitalization or death from any cause through Day 28. The analysis was conducted in the modified intent-to-treat (mITT) analysis set (all treated subjects with onset of symptoms ≤3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), the mITT1 analysis set (all treated subjects with onset of symptoms ≤5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), and the mITT2 analysis set (all treated subjects with onset of symptoms ≤5 days).

A total of 2,246 subjects were randomized to receive either PAXLOVID or placebo. At baseline, mean age was 46 years; 51% were male; 72% were White, 5% were Black, and 14% were Asian; 45% were Hispanic or Latino; 66% of subjects had onset of symptoms ≤3 days from initiation of study treatment; 47% of subjects were serological negative at baseline; the mean (SD) baseline viral load was 4.63 log_{10} copies/mL (2.87); 26% of subjects had a baseline viral load of >10^7 (units); 6% of subjects either received or were expected to receive COVID-19 therapeutic monoclonal antibody treatment at the time of randomization and were excluded from the mITT and mITT1 analyses.

The baseline demographic and disease characteristics were balanced between the PAXLOVID and placebo groups.

Table 8 provides results of the primary endpoint in mITT1 analysis population. For the primary endpoint, the relative risk reduction in the mITT1 analysis population for PAXLOVID compared to placebo was 88% (95% CI: 75%, 94%).

Table 8: Efficacy Results in Non-Hospitalized Adults with COVID-19 Dosed within 5 Days of Symptom Onset who Did Not Receive COVID-19 Monoclonal Antibody Treatment at Baseline (mITT1 Analysis Set)

<table>
<thead>
<tr>
<th></th>
<th>PAXLOVID (N=1,039)</th>
<th>Placebo (N=1,046)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 related hospitalization or death from any cause through Day 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>8 (0.8%)</td>
<td>66 (6.3%)</td>
</tr>
<tr>
<td>Reduction relative to placeboa [95% CI], %</td>
<td>-5.62 (-7.21, -4.03)</td>
<td></td>
</tr>
<tr>
<td>All-cause mortality through Day 28, %</td>
<td>0</td>
<td>12 (1.1%)</td>
</tr>
</tbody>
</table>

Abbreviations: CI=confidence interval.

The determination of primary efficacy was based on a planned interim analysis of 780 subjects in mITT population. The estimated risk reduction was -6.3% with a 95% CI of (-9.0%, -3.6%) and 2-sided p-value <0.0001.

a. The estimated cumulative proportion of participants hospitalized or death by Day 28 was calculated for each treatment group using the Kaplan-Meier method, where subjects without hospitalization and death status through Day 28 were censored at the time of study discontinuation.

Consistent results were observed in the mITT and mITT2 analysis populations. A total of 1,379 subjects were included in the mITT analysis population. The event rates were 5/697 (0.72%) in the PAXLOVID group, and 44/682 (6.45%) in the placebo group. The primary SARS-CoV-2 variant across both treatment arms was Delta (98%), including clades 21J, 21A, and 21I.
Similar trends have been observed across subgroups of subjects (see Figure 1). These subgroup analyses are considered exploratory.

**Figure 1: Adults with COVID-19 Dosed within 5 Days of Symptom Onset with COVID-19-Related Hospitalization or Death from Any Cause Through Day 28 (Protocol C4671005)**

Relative to placebo, PAXLOVID treatment was associated with an approximately 0.9 log_{10} copies/mL greater decline in viral RNA levels in nasopharyngeal samples through Day 5, with similar results observed in the mITT, mITT1, and mITT2 analysis populations.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

**How Supplied**

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in two different Dose Packs.

Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.
<table>
<thead>
<tr>
<th>Dose Pack</th>
<th>Content</th>
<th>NDC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>300 mg nirmatrelvir; 100 mg ritonavir</td>
<td>Each Carton Contains: 30 tablets divided in 5 daily-dose blister cards</td>
<td>0069-1085-30</td>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.</td>
</tr>
<tr>
<td></td>
<td>Or</td>
<td>0069-0345-30</td>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White to off-white, capsule-shaped, film-coated tablets debossed with “H” on one side and “R9” on the other side.</td>
</tr>
<tr>
<td></td>
<td>Each Blister Card contains: 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each)</td>
<td>0069-1085-06</td>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.</td>
</tr>
<tr>
<td></td>
<td>Or</td>
<td>0069-0345-06</td>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White to off-white, capsule-shaped, film-coated tablets debossed with “H” on one side and “R9” on the other side.</td>
</tr>
<tr>
<td>150 mg nirmatrelvir; 100 mg ritonavir</td>
<td>Each Carton Contains: 20 tablets divided in 5 daily-dose blister cards</td>
<td>0069-1101-20</td>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.</td>
</tr>
</tbody>
</table>
Each Blister Card contains:

<table>
<thead>
<tr>
<th>2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each)</th>
<th>0069-1101-04</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with &quot;PFE&quot; on one side and &quot;3CL&quot; on the other side. Ritonavir tablets: White film-coated ovaloid tablets debossed with the “a” logo and the code NK.</td>
<td></td>
</tr>
</tbody>
</table>

a. Indicates which tablets need to be taken in the morning and evening.

Storage and Handling

Store at USP controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

17 PATIENT COUNSELING INFORMATION

As a healthcare practitioner, you must communicate to the patient and/or caregiver information consistent with the "FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS" and provide them with a copy of this Fact Sheet prior to administration of PAXLOVID.

Allergic Reactions/Hypersensitivity

Inform patients that hypersensitivity reactions have been reported, even following a single dose of PAXLOVID. Advise them to discontinue the drug and to inform their healthcare provider at the first sign of a skin rash, hives or other skin reactions, difficulty in swallowing or breathing, any swelling suggesting angioedema (for example, swelling of the lips, tongue, face, tightness of the throat, hoarseness), or other symptoms of an allergic reaction [see Warnings and Precautions (5.2)].

Dosage Modification in Patients with Moderate Renal Impairment

To ensure appropriate dosing in patients with moderate renal impairment, instruct such patients that they will be taking one 150 mg nirmatrelvir tablet with one 100 mg ritonavir tablet together twice daily for 5 days.

In the event that the PAXLOVID 150 mg;100 mg dose pack is unavailable: pharmacist should refer to the provided instructions entitled “IMPORTANT PAXLOVID™ EUA DISPENSING INFORMATION FOR PATIENTS WITH MODERATE RENAL IMPAIRMENT” for dispensing of PAXLOVID to patients with moderate renal impairment [see Dosage and Administration (2.2)] and patients should be informed that their daily blister card has been altered to ensure they receive the correct dose.

Drug Interactions

Inform patients that PAXLOVID may interact with some drugs and is contraindicated for use with some drugs; therefore, patients should be advised to report to their healthcare provider the use of any prescription, non-prescription medication, or herbal products [see Dosage and Administration (2.4), Contraindications (4), Warnings and Precautions (5.1), and Drug Interactions (7)].
Administration Instructions

Inform patients to take PAXLOVID with or without food as instructed. Advise patients to swallow all tablets for PAXLOVID whole and not to chew, break, or crush the tablets. Alert the patient of the importance of completing the full 5-day treatment course and to continuing isolation in accordance with public health recommendations to maximize viral clearance and minimize transmission of SARS-CoV-2. If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose [see Dosage and Administration (2.1)].

18 MANUFACTURER INFORMATION

For general questions, visit the website or call the telephone number provided below.

<table>
<thead>
<tr>
<th>Website</th>
<th>Telephone number</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://www.COVID19oralRx.com">www.COVID19oralRx.com</a></td>
<td>1-877-219-7225</td>
</tr>
<tr>
<td></td>
<td>(1-877-C19-PACK)</td>
</tr>
</tbody>
</table>

For Medical Information about PAXLOVID, please visit www.pfizermedinfo.com or call 1-800-438-1985.

LAB-1492-6.2

Revised: 14 April 2022